ocrelizumab

stop sign knerri61Pixabay

Biotech

MediciNova's ibudilast flops in methamphetamine dependence trial

MediciNova's ibudilast missed its primary endpoint of methamphetamine abstinence in a 12-week phase 2 trial.

Amirah Al Idrus Mar 29, 2018 10:23am

Roche HQ

Roche MS candidate beats Rebif in latest PhIII as 2016 FDA decision awaits

Sep 14, 2016 6:41am